Get started
Author

Nikita Dave

Uveal melanoma: epidemiology, etiology, and treatment of primary disease
2017 · Benjamin A Krantz, Nikita Dave, et al. · Clinical ophthalmology · 403
PDF
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
2025 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 41
Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain
2019 · Tamar B. Nobel, Nikita Dave, et al. · The Annals of Thoracic Surgery · 28
PDF
Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
2024 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 15
Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis
2025 · Rebecca E. Ward, Nikita Dave, et al. · Clinical Nuclear Medicine · 4
Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma
2025 · Nikita K. Dave, Veronica Carvajal, et al. · Blood Neoplasia · 2
Clinical and biologic activity of soy protein powder (SPP) in healthy male volunteers: effect on testosterone and luteinizing hormone (LH)
2004 · S. Goodin, F. Shen, et al. · Journal of Clinical Oncology · 2
Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study
2025 · Taylor Brooks, Agrima Mian, et al. · Blood · 1
Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.
2025 · XI Yang, Yasmin Karimi, et al. · Blood · 1
PDF
707 | Clinical Outcomes With Bispecific Antibodies in the Management of Secondary Central Nervous System Lymphoma
2025 · N. K. Dave, P. Carvajal, et al. · Hematological Oncology · 1
PDF
Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy
2022 · Nikita Dave, Jennifer J.D. Morrissette, et al. · Blood · 1
Survival after Chimeric Antigen Receptor T-cell Therapy Is Predicted By Fried’s Frailty Phenotype
2026 · Nikita K Dave, Shannon H. Gier, et al. · Transplantation and Cellular Therapy
Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study
2025 · Nikita Dave, Shannon Gier, et al. · Blood
PDF
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
2025 · Nikita Dave, Imran Nizamuddin, et al. · Blood
PDF
A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study
2025 · Nikita Dave, Alexandra Dreyfuss, et al. · Blood
PDF
714 | Cart Cell Therapy in the Management of Secondary Central Nervous System Lymphoma
2025 · N. K. Dave, P. Carvajal, et al. · Hematological Oncology
PDF
340 | Prolonged Methotrexate, Temozolomide and Rituximab in Secondary Central Nervous System Lymphoma
2025 · N. K. Dave, P. Carvajal, et al. · Hematological Oncology
PDF
Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania
2024 · Nikita Dave, Veronica Carvajal, et al. · Blood
Management of Solid Pseudopapillary Tumors of the Pancreas: Experience from a Single Institution
2019 · Jin K. Kim, Nikita Dave, et al. · The American Surgeon
Works count: 19
Citation count: 499
H-index: 4
I10-index: 4
Year
Topic
Type